Alpine Immune Sciences (STU:34LA) Dividends per Share : €0.00 (TTM As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Alpine Immune Sciences Dividends per Share?

Alpine Immune Sciences's dividends per share for the three months ended in Dec. 2023 was €0.00. Its dividends per share for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00. Its Dividend Payout Ratio for the three months ended in Dec. 2023 was 0.00. As of today, Alpine Immune Sciences's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

Alpine Immune Sciences Dividends per Share Historical Data

The historical data trend for Alpine Immune Sciences's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alpine Immune Sciences Dividends per Share Chart

Alpine Immune Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dividends per Share

Get a 7-Day Free Trial

Alpine Immune Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Dividends per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Alpine Immune Sciences's Dividends per Share

For the Biotechnology subindustry, Alpine Immune Sciences's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alpine Immune Sciences's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alpine Immune Sciences's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Alpine Immune Sciences's Dividend Yield % falls into.

Alpine Immune Sciences Dividends per Share Calculation

Dividends paid to per common share.

Alpine Immune Sciences (STU:34LA) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Alpine Immune Sciences's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2023 )	/	EPS without NRI (Q: Dec. 2023 )
	=	0	/	0.138
	=	0.00

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

Alpine Immune Sciences Dividends per Share Related Terms

Thank you for viewing the detailed overview of Alpine Immune Sciences's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Alpine Immune Sciences (STU:34LA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alpine Immune Sciences Inc (STU:34LA) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

ALPN:USA

Address

188 East Blaine Street, Suite 200, Seattle, WA, USA, 98102

Website

https://www.alpineimmunesciences.com

Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company dedicated to discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. Its approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its pipeline candidates are; ALPN-303, or povetacicept, is a dual antagonist of the B cell activating factor, or BAFF, and a proliferation-inducing ligand, or APRIL, cytokines, which play key roles in the activation, development, and survival of B cells, and ALPN-101, or acazicolcept, is a dual Inducible T cell Costimulator, or ICOS, and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.

Alpine Immune Sciences (STU:34LA) Headlines

No Headlines